Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPhase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors
Annals of Oncology, 11/04/09
Schmid P et al. – Sagopilone (ZK–EPO) is a fully synthetic microtubule–stabilizing agent that has demonstrated high antitumor activity in preclinical models. This first–in–human phase I study aimed to determine the maximum tolerated dose (MTD) and dose–limiting toxic effects (DLTs) of 3–weekly sagopilone treatment. These data demonstrate that sagopilone therapy is feasible and well tolerated. The recommended dose for phase II studies is 16.53 mg/m^2, once every 3 weeks.
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor